DENVER, Dec. 13 /CNW/ - Embla Systems, a leader in the field of sleep
diagnostic software and equipment announced today the signing of an exclusive
agreement with the Beth Israel Deaconess Medical Center (BIDMC) for the
distribution of the Cardio Pulmonary Coupling (CPC) technology developed by
Drs. Robert Thomas, Ary Goldberger, C-K. Peng, and Mr. Joseph Mietus.
CPC technology represents a breakthrough in how sleep can be visualized,
by presenting a simple and accurate picture of sleep oscillations and
interactions instead of the tedious manual sleep stage scoring and counting of
respiratory events that has been the standard for the last 40 years. The
analysis has been validated using over 10,000 sleep studies. "The CPC
technology is not a sleep-stage or respiratory event detector but [it] does
provide a dynamic measure of sleep state-modulated cardio-pulmonary
interactions," says Dr. Robert Thomas. "As the technique is automated,
inter-scorer reliability is eliminated as a problem. The technique can track
dynamic sleep physiology, and provide a unique ambulatory measure of sleep
"With the anticipated introduction of reimbursement for home testing, the
integration of this technology into Embla's existing product line confirms our
dominant position in this market place," said David Baker, President and CEO
of Embla. "In addition, the technology will allow us to develop very low cost
and reliable diagnostic tools to assist clinicians in diagnosing the presence
of sleep apnea among the huge population of undiagnosed people who suffer from
this condition, while allowing an unprecedented method to monitor treatment
effects on sleep quality and respiratory dynamics in the 13 million or so
users of CPAP machines in the US alone".
The CPC technology will give physicians the "Sleep Health" of a patient
and to evaluate if the patient has Obstructive, Central or Complex Sleep
Apnea. The clinical significance of such a simple and low cost test is that it
will accelerate necessary medical assistance to those patients in need of
diagnosis for sleep disorder breathing at a fraction of today's current cost.
Moreover, clinicians will benefit from the phenotyping capabilities of the
technology to enhance diagnostic accuracy of non-obstructive forms of sleep
disorder breathing (including heart failure patients), recommend appropriate
treatment, and evaluate treatment efficacy. Over the next 12 to 18 months
Embla will be developing the technology into their existing laboratory based
Polysomnography (PSG) equipment and their portable home monitoring equipment.
Beth Israel Deaconess Medical Center is a patient care, teaching and
research affiliate of Harvard Medical School, and consistently ranks among the
top four in National Institutes of Health funding among independent hospitals
nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and
is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the
official hospital of the Boston Red Sox.
For more information, please visit http://www.bidmc.harvard.edu.
Embla's alliance with major academic institutions for intellectual
technology ensures attaining the business and strategic goals of the company
to advance the science of sleep medicine and to bring evidence based medicine
into general practice.
Embla Systems is headquartered in Denver Colorado and is a leading
provider of Sleep Diagnostic Equipment in the world. For more information,
please visit http://www.embla.com
Embla Systems is a part of Flaga Group, a public company listed on the
Icelandic Stock Exchange.
For more information, please visit http://www.flagagroup.com
For further information:
For further information: David Baker, CEO of Embla Systems, (480)
236-4705, Web Site: http://www.embla.com, http://www.flagagroup.com